Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach

Masami Kadowaki, Takafumi Sangai, Takeshi Nagashima, Masahiro Sakakibara, Hideyuki Yoshitomi, Shigetsugu Takano, Kazuyuki Sogawa, Hiroshi Umemura, Koya Fushimi, Yukio Nakatani, Fumio Nomura, Masaru Miyazaki

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Purpose: Breast cancer is the most frequent malignancy in women. However, no useful serum markers with high sensitivity and specificity for the detection of early breast cancer have been identified. The search for biological markers of early breast cancer is of continual interest in experimental and clinical breast cancer research. We recently described a simple and highly reproducible three-step proteome analysis for identifying potential disease-marker candidates among the low-abundance serum proteins. Methods: Serum samples from breast ductal carcinoma in situ (DCIS) patients and normal controls were subjected to a three-step serum proteome analysis. The steps were the following: first, immunodepletion of most abundant proteins; second, fractionation using reverse-phase high-performance liquid chromatography; and third, separation using two-dimensional electrophoresis (2-DE). Differences revealed by protein staining were further confirmed by Western blotting, immunohistochemical staining, and enzyme-linked immunosorbent assays (ELISA). Results: Twenty-two upregulated and 26 downregulated spots were detected on the 2-DE gels, and a total of 33 proteins were identified by liquid chromatography and tandem mass spectrometry. Western blotting confirmed that the level of vitronectin was significantly increased in DCIS patients compared with that of normal controls. Immunohistochemical staining of vitronectin in breast cancer tissue revealed high expression in small vessel walls surrounding cancer cells and the extracellular matrix of stroma. Moreover, vitronectin serum concentrations, as measured by ELISA, were significantly increased in patients with DCIS or more advanced breast cancer compared with those of normal controls. Conclusions: Vitronectin could serve as a promising serum marker for the detection of primary breast cancer.

Original languageEnglish
Pages (from-to)1105-1115
Number of pages11
JournalJournal of Cancer Research and Clinical Oncology
Volume137
Issue number7
DOIs
Publication statusPublished - Jul 2011
Externally publishedYes

Fingerprint

Vitronectin
Early Detection of Cancer
Proteomics
Biomarkers
Breast Neoplasms
Carcinoma, Intraductal, Noninfiltrating
Proteome
Staining and Labeling
Serum
Enzyme-Linked Immunosorbent Assay
Far-Western Blotting
Proteins
Reverse-Phase Chromatography
Tandem Mass Spectrometry
Liquid Chromatography
Extracellular Matrix
Electrophoresis
Blood Proteins
Neoplasms
Down-Regulation

Keywords

  • Breast cancer
  • Immunodepletion
  • Proteomics
  • Serum marker
  • Vitronectin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach. / Kadowaki, Masami; Sangai, Takafumi; Nagashima, Takeshi; Sakakibara, Masahiro; Yoshitomi, Hideyuki; Takano, Shigetsugu; Sogawa, Kazuyuki; Umemura, Hiroshi; Fushimi, Koya; Nakatani, Yukio; Nomura, Fumio; Miyazaki, Masaru.

In: Journal of Cancer Research and Clinical Oncology, Vol. 137, No. 7, 07.2011, p. 1105-1115.

Research output: Contribution to journalArticle

Kadowaki, M, Sangai, T, Nagashima, T, Sakakibara, M, Yoshitomi, H, Takano, S, Sogawa, K, Umemura, H, Fushimi, K, Nakatani, Y, Nomura, F & Miyazaki, M 2011, 'Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach', Journal of Cancer Research and Clinical Oncology, vol. 137, no. 7, pp. 1105-1115. https://doi.org/10.1007/s00432-010-0974-9
Kadowaki, Masami ; Sangai, Takafumi ; Nagashima, Takeshi ; Sakakibara, Masahiro ; Yoshitomi, Hideyuki ; Takano, Shigetsugu ; Sogawa, Kazuyuki ; Umemura, Hiroshi ; Fushimi, Koya ; Nakatani, Yukio ; Nomura, Fumio ; Miyazaki, Masaru. / Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach. In: Journal of Cancer Research and Clinical Oncology. 2011 ; Vol. 137, No. 7. pp. 1105-1115.
@article{df757e11f492447c94e3b37bf2a99bec,
title = "Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach",
abstract = "Purpose: Breast cancer is the most frequent malignancy in women. However, no useful serum markers with high sensitivity and specificity for the detection of early breast cancer have been identified. The search for biological markers of early breast cancer is of continual interest in experimental and clinical breast cancer research. We recently described a simple and highly reproducible three-step proteome analysis for identifying potential disease-marker candidates among the low-abundance serum proteins. Methods: Serum samples from breast ductal carcinoma in situ (DCIS) patients and normal controls were subjected to a three-step serum proteome analysis. The steps were the following: first, immunodepletion of most abundant proteins; second, fractionation using reverse-phase high-performance liquid chromatography; and third, separation using two-dimensional electrophoresis (2-DE). Differences revealed by protein staining were further confirmed by Western blotting, immunohistochemical staining, and enzyme-linked immunosorbent assays (ELISA). Results: Twenty-two upregulated and 26 downregulated spots were detected on the 2-DE gels, and a total of 33 proteins were identified by liquid chromatography and tandem mass spectrometry. Western blotting confirmed that the level of vitronectin was significantly increased in DCIS patients compared with that of normal controls. Immunohistochemical staining of vitronectin in breast cancer tissue revealed high expression in small vessel walls surrounding cancer cells and the extracellular matrix of stroma. Moreover, vitronectin serum concentrations, as measured by ELISA, were significantly increased in patients with DCIS or more advanced breast cancer compared with those of normal controls. Conclusions: Vitronectin could serve as a promising serum marker for the detection of primary breast cancer.",
keywords = "Breast cancer, Immunodepletion, Proteomics, Serum marker, Vitronectin",
author = "Masami Kadowaki and Takafumi Sangai and Takeshi Nagashima and Masahiro Sakakibara and Hideyuki Yoshitomi and Shigetsugu Takano and Kazuyuki Sogawa and Hiroshi Umemura and Koya Fushimi and Yukio Nakatani and Fumio Nomura and Masaru Miyazaki",
year = "2011",
month = "7",
doi = "10.1007/s00432-010-0974-9",
language = "English",
volume = "137",
pages = "1105--1115",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach

AU - Kadowaki, Masami

AU - Sangai, Takafumi

AU - Nagashima, Takeshi

AU - Sakakibara, Masahiro

AU - Yoshitomi, Hideyuki

AU - Takano, Shigetsugu

AU - Sogawa, Kazuyuki

AU - Umemura, Hiroshi

AU - Fushimi, Koya

AU - Nakatani, Yukio

AU - Nomura, Fumio

AU - Miyazaki, Masaru

PY - 2011/7

Y1 - 2011/7

N2 - Purpose: Breast cancer is the most frequent malignancy in women. However, no useful serum markers with high sensitivity and specificity for the detection of early breast cancer have been identified. The search for biological markers of early breast cancer is of continual interest in experimental and clinical breast cancer research. We recently described a simple and highly reproducible three-step proteome analysis for identifying potential disease-marker candidates among the low-abundance serum proteins. Methods: Serum samples from breast ductal carcinoma in situ (DCIS) patients and normal controls were subjected to a three-step serum proteome analysis. The steps were the following: first, immunodepletion of most abundant proteins; second, fractionation using reverse-phase high-performance liquid chromatography; and third, separation using two-dimensional electrophoresis (2-DE). Differences revealed by protein staining were further confirmed by Western blotting, immunohistochemical staining, and enzyme-linked immunosorbent assays (ELISA). Results: Twenty-two upregulated and 26 downregulated spots were detected on the 2-DE gels, and a total of 33 proteins were identified by liquid chromatography and tandem mass spectrometry. Western blotting confirmed that the level of vitronectin was significantly increased in DCIS patients compared with that of normal controls. Immunohistochemical staining of vitronectin in breast cancer tissue revealed high expression in small vessel walls surrounding cancer cells and the extracellular matrix of stroma. Moreover, vitronectin serum concentrations, as measured by ELISA, were significantly increased in patients with DCIS or more advanced breast cancer compared with those of normal controls. Conclusions: Vitronectin could serve as a promising serum marker for the detection of primary breast cancer.

AB - Purpose: Breast cancer is the most frequent malignancy in women. However, no useful serum markers with high sensitivity and specificity for the detection of early breast cancer have been identified. The search for biological markers of early breast cancer is of continual interest in experimental and clinical breast cancer research. We recently described a simple and highly reproducible three-step proteome analysis for identifying potential disease-marker candidates among the low-abundance serum proteins. Methods: Serum samples from breast ductal carcinoma in situ (DCIS) patients and normal controls were subjected to a three-step serum proteome analysis. The steps were the following: first, immunodepletion of most abundant proteins; second, fractionation using reverse-phase high-performance liquid chromatography; and third, separation using two-dimensional electrophoresis (2-DE). Differences revealed by protein staining were further confirmed by Western blotting, immunohistochemical staining, and enzyme-linked immunosorbent assays (ELISA). Results: Twenty-two upregulated and 26 downregulated spots were detected on the 2-DE gels, and a total of 33 proteins were identified by liquid chromatography and tandem mass spectrometry. Western blotting confirmed that the level of vitronectin was significantly increased in DCIS patients compared with that of normal controls. Immunohistochemical staining of vitronectin in breast cancer tissue revealed high expression in small vessel walls surrounding cancer cells and the extracellular matrix of stroma. Moreover, vitronectin serum concentrations, as measured by ELISA, were significantly increased in patients with DCIS or more advanced breast cancer compared with those of normal controls. Conclusions: Vitronectin could serve as a promising serum marker for the detection of primary breast cancer.

KW - Breast cancer

KW - Immunodepletion

KW - Proteomics

KW - Serum marker

KW - Vitronectin

UR - http://www.scopus.com/inward/record.url?scp=79959769545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959769545&partnerID=8YFLogxK

U2 - 10.1007/s00432-010-0974-9

DO - 10.1007/s00432-010-0974-9

M3 - Article

C2 - 21253761

AN - SCOPUS:79959769545

VL - 137

SP - 1105

EP - 1115

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 7

ER -